TIGIT and neoplasm: It was demonstrated that dual PD-1/TIGIT blockade potently increases tumor antigen-specific CD8+ T cell expansion and function in vitro and promotes tumor rejection in mouse tumor models leading to a cure rate up to 100% [16].